The authors evaluated the FGFR3 mutation status in a cohort of patients who underwent radical cystectomy and evaluated its potential as a marker for favorable disease. Mutations in FGFR3 are common in non-muscle invasive bladder cancer, but relatively rare in invasive tumors.
In this study, 13% of the 290 patients undergoing radical cystectomy had mutations in the FGFR3 gene and these tumors had lower pathologic stage and rare nodal metastatses compared to tumors with normal FGFR3.
Presented by Bas W. van Rhijn, et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA
Reported for UroToday by David P. Wood Jr., MD, Professor, Department of Urology, University of Michigan Health System.
View Full AUA 2011 Meeting Coverage
